WO2006099169A3 - Novel liposome compositions - Google Patents
Novel liposome compositions Download PDFInfo
- Publication number
- WO2006099169A3 WO2006099169A3 PCT/US2006/008650 US2006008650W WO2006099169A3 WO 2006099169 A3 WO2006099169 A3 WO 2006099169A3 US 2006008650 W US2006008650 W US 2006008650W WO 2006099169 A3 WO2006099169 A3 WO 2006099169A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liposome compositions
- novel liposome
- containing compositions
- lipid
- targeted liposomes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006223329A AU2006223329B2 (en) | 2005-03-10 | 2006-03-08 | Novel liposome compositions |
BRPI0608297-1A BRPI0608297A2 (en) | 2005-03-10 | 2006-03-08 | liposome compositions |
CN2006800159670A CN101170995B (en) | 2005-03-10 | 2006-03-08 | Novel liposome compositions |
NZ561569A NZ561569A (en) | 2005-03-10 | 2006-03-08 | Novel liposome compositions comprising SuccNomegaPE:NomegaPE:additional lipids and TF-NomegaPE:NomegaPE:additional lipids |
PL06737793T PL1863448T3 (en) | 2005-03-10 | 2006-03-08 | Novel liposome compositions |
CA002600446A CA2600446A1 (en) | 2005-03-10 | 2006-03-08 | Novel liposome compositions |
MX2007010996A MX2007010996A (en) | 2005-03-10 | 2006-03-08 | Novel liposome compositions. |
KR1020077023219A KR101352490B1 (en) | 2005-03-10 | 2006-03-08 | Novel liposome compositions |
SI200631892T SI1863448T1 (en) | 2005-03-10 | 2006-03-08 | Novel liposome compositions |
JP2008500977A JP5438317B2 (en) | 2005-03-10 | 2006-03-08 | Novel liposome composition |
DK06737793.7T DK1863448T3 (en) | 2005-03-10 | 2006-03-08 | NEW LIPOSOM COMPOSITIONS |
ES06737793.7T ES2529453T3 (en) | 2005-03-10 | 2006-03-08 | New liposome compositions |
EP06737793.7A EP1863448B1 (en) | 2005-03-10 | 2006-03-08 | Novel liposome compositions |
NO20075136A NO20075136L (en) | 2005-03-10 | 2007-10-09 | New liposome preparations |
HK08105936.8A HK1111625A1 (en) | 2005-03-10 | 2008-05-28 | Novel liposome compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005067469A JP2006248978A (en) | 2005-03-10 | 2005-03-10 | New liposome preparation |
JP2005-67469 | 2005-03-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006099169A2 WO2006099169A2 (en) | 2006-09-21 |
WO2006099169A3 true WO2006099169A3 (en) | 2007-02-22 |
Family
ID=36992280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/008650 WO2006099169A2 (en) | 2005-03-10 | 2006-03-08 | Novel liposome compositions |
Country Status (22)
Country | Link |
---|---|
US (3) | US7829113B2 (en) |
EP (1) | EP1863448B1 (en) |
JP (2) | JP2006248978A (en) |
KR (1) | KR101352490B1 (en) |
CN (1) | CN101170995B (en) |
AU (1) | AU2006223329B2 (en) |
BR (1) | BRPI0608297A2 (en) |
CA (1) | CA2600446A1 (en) |
CY (1) | CY1116075T1 (en) |
DK (1) | DK1863448T3 (en) |
ES (1) | ES2529453T3 (en) |
HK (1) | HK1111625A1 (en) |
HU (1) | HUE024290T2 (en) |
MX (1) | MX2007010996A (en) |
NO (1) | NO20075136L (en) |
NZ (1) | NZ561569A (en) |
PL (1) | PL1863448T3 (en) |
PT (1) | PT1863448E (en) |
RU (1) | RU2454229C2 (en) |
SI (1) | SI1863448T1 (en) |
WO (1) | WO2006099169A2 (en) |
ZA (1) | ZA200708600B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7829113B2 (en) | 2005-03-10 | 2010-11-09 | Mebiopharm Co., Ltd. | Liposome compositions |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101462819B1 (en) | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | Liposomes useful for drug delivery |
CN101209243B (en) * | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术(石家庄)有限公司 | Liposome medicament and preparation thereof |
WO2009097011A1 (en) * | 2007-08-17 | 2009-08-06 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
HUE027443T2 (en) * | 2007-09-10 | 2016-10-28 | Boston Biomedical Inc | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
TWI468188B (en) | 2008-01-30 | 2015-01-11 | Univ Tokushima | Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation |
WO2011005769A1 (en) * | 2009-07-06 | 2011-01-13 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
WO2011038068A1 (en) * | 2009-09-23 | 2011-03-31 | Formatech, Inc. | Methods for the preparation of liposomes |
US10143652B2 (en) * | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
WO2011102904A1 (en) * | 2010-02-19 | 2011-08-25 | Robert Shorr | Imageable lipid-oil-water nanoemulsion therapeutic delivery system |
RU2591823C2 (en) | 2010-03-19 | 2016-07-20 | Бостон Байомедикал, Инк. | Novel methods for targeting cancer stem cells |
EP2558108A1 (en) * | 2010-04-12 | 2013-02-20 | Ramot at Tel-Aviv University Ltd | Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders |
EP2637697A4 (en) | 2010-11-12 | 2016-07-13 | Cour Pharmaceuticals Dev Company | Modified immune-modulating particles |
WO2012153616A1 (en) * | 2011-05-10 | 2012-11-15 | 国立大学法人北海道大学 | Lipid membrane structure capable of imigrating to target cell and method for producing same, and method for screening for substance exhibiting effect thereof in target cell |
JP5983608B2 (en) * | 2011-07-15 | 2016-09-06 | コニカミノルタ株式会社 | Liposome-containing preparation using dissolution aid and method for producing the same |
EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US20150216998A1 (en) * | 2012-01-01 | 2015-08-06 | Ramot At Tel-Aviv University Ltd. | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
PT2863942T (en) * | 2012-06-21 | 2019-07-17 | Univ Northwestern | Peptide conjugated particles |
SG11201501010QA (en) | 2012-08-10 | 2015-04-29 | Taiho Pharmaceutical Co Ltd | Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same |
WO2014092858A1 (en) * | 2012-12-12 | 2014-06-19 | Temple University - Of The Commonwealth System Of Higher Education | Compositions and methods for treatment of cancer |
CN103083239B (en) * | 2012-12-26 | 2015-11-25 | 中国人民解放军第四军医大学 | A kind of bufalin liposome and its preparation method and application |
TWI718086B (en) | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
CN105263476A (en) | 2013-03-13 | 2016-01-20 | 库尔制药开发公司 | Immune-modifying particles for the treatment of inflammation |
BR112015022415A2 (en) * | 2013-03-13 | 2017-07-18 | Mallinckrodt Llc | Liposomal cisplatin compositions for cancer therapy |
JP6341987B2 (en) * | 2013-03-13 | 2018-06-13 | マリンクロッド エルエルシー | Liposomal oxaliplatin composition for cancer treatment |
EP2983790A2 (en) | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
KR20230008909A (en) | 2013-08-13 | 2023-01-16 | 노쓰웨스턴유니버시티 | Peptide conjugated particles |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
ES2670983T3 (en) | 2013-11-07 | 2018-06-04 | Editas Medicine, Inc. | Methods and compositions related to CRISPR with rRNA guiding |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
WO2015183357A2 (en) * | 2014-02-21 | 2015-12-03 | The Curators Of The University Of Missouri | Compositions and methods for boron neutron capture therapy |
EP4079847A1 (en) | 2014-07-30 | 2022-10-26 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
US10098813B2 (en) * | 2014-09-03 | 2018-10-16 | Sun Pharmaceutical Industries Limited | Perfusion dosage form |
EP3212165B1 (en) | 2014-10-30 | 2024-02-28 | President and Fellows of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US9816080B2 (en) | 2014-10-31 | 2017-11-14 | President And Fellows Of Harvard College | Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs) |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
WO2016208481A1 (en) | 2015-06-24 | 2016-12-29 | 日本化薬株式会社 | Novel platinum (iv) complex |
ES2848118T3 (en) | 2015-08-20 | 2021-08-05 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a PARP inhibitor for the treatment of cancer |
BR112018002941B1 (en) | 2015-08-21 | 2023-12-05 | Ipsen Biopharm Ltd | USE OF LIPOSOMAL IRINOTECAN, OXALIPLATIN, LEUCOVORIN AND 5-FLUOROURACIL IN FIRST-LINE TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS |
US10596191B2 (en) | 2015-09-14 | 2020-03-24 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of hexa-coordinated platinum complex |
MA42991A (en) | 2015-10-16 | 2018-08-22 | Ipsen Biopharm Ltd | STABILIZATION OF PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN |
CN108513575A (en) | 2015-10-23 | 2018-09-07 | 哈佛大学的校长及成员们 | Nucleobase editing machine and application thereof |
WO2017087685A1 (en) * | 2015-11-20 | 2017-05-26 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
CA3009130A1 (en) | 2015-12-22 | 2017-06-29 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of sulfoxide derivative-coordinated platinum(ii) complex |
CN106995465B (en) | 2016-01-25 | 2019-11-01 | 沈阳药科大学 | A kind of compound and its application and a kind of platinum complexes and its liposome |
CN109312341B (en) | 2016-03-07 | 2024-02-27 | 美国政府(由卫生和人类服务部的部长所代表) | Micrornas and methods of use thereof |
JP6606600B2 (en) * | 2016-04-15 | 2019-11-13 | 富士フイルム株式会社 | Microneedle array |
EP3493790A4 (en) * | 2016-08-02 | 2020-03-25 | Curirx Inc. | Methods for the preparation of liposomes |
KR20230095129A (en) | 2016-08-03 | 2023-06-28 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Adenosine nucleobase editors and uses thereof |
EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
AU2017308158B2 (en) | 2016-08-12 | 2023-08-10 | L.E.A.F. Holdings Group Llc | Alpha and gamma-D polyglutamated antifolates and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
EA201990979A1 (en) | 2016-11-02 | 2019-09-30 | Ипсен Биофарм Лтд. | METHODS FOR TREATING GASTROINTESTINAL CANCER USING COMBINATION TYPES OF THERAPY CONTAINING LIPOSOMAL IRINOTECAN AND OXALALPLATIN |
WO2018087720A1 (en) | 2016-11-14 | 2018-05-17 | Novartis Ag | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
JP2020510439A (en) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Base-editing factor from cytosine to guanine |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
CN110869006A (en) * | 2017-05-12 | 2020-03-06 | 库里纳尔克斯有限公司 | Method for preparing liposome containing medicine |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
US10646464B2 (en) | 2017-05-17 | 2020-05-12 | Boston Biomedical, Inc. | Methods for treating cancer |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | Alpha polyglutamated pralatrexate and uses thereof |
CN111954531A (en) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | Alpha polyglutamated pemetrexed and its use |
WO2019160734A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
CN108524450A (en) * | 2018-04-16 | 2018-09-14 | 温州医科大学 | Oxaliplatin and MDC1-AS based on magnetic temperature-sensitive cationic-liposome transmit the preparation and application of pharmaceutical carrier altogether |
KR20210068485A (en) | 2018-09-28 | 2021-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
CA3114699A1 (en) | 2018-10-09 | 2020-04-16 | The University Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
WO2020191249A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
CN111721841B (en) * | 2019-03-19 | 2022-07-12 | 海南长安国际制药有限公司 | Detection of lobaplatin-related substances |
CN110292563B (en) * | 2019-06-12 | 2021-07-16 | 兰州大学 | Method for inducing cancer cell apoptosis by using folic acid heat-sensitive liposome-based anion carrier |
MX2022012265A (en) | 2020-04-02 | 2023-01-11 | Mirecule Inc | Targeted inhibition using engineered oligonucleotides. |
DE112021002672T5 (en) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE |
CN112129871B (en) * | 2020-09-04 | 2021-06-15 | 斯微(上海)生物科技有限公司 | Method for detecting contents of DOPE and M5 phospholipids in composite phospholipid liposome |
CN112870164B (en) * | 2021-01-25 | 2021-12-17 | 山东大学 | Double-targeting drug-loaded liposome and preparation method and application thereof |
WO2023196851A1 (en) | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986004232A1 (en) * | 1985-01-18 | 1986-07-31 | Cooper-Lipotech, Inc. | Liposome composition and method |
US5419914A (en) * | 1990-10-09 | 1995-05-30 | Vestar, Inc. | Phospholipid analogue vesicle |
WO1996021658A1 (en) * | 1995-01-09 | 1996-07-18 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
US5891468A (en) * | 1996-10-11 | 1999-04-06 | Sequus Pharmaceuticals, Inc. | Fusogenic liposome compositions and method |
EP1209469A1 (en) * | 2000-11-22 | 2002-05-29 | Vectron Therapeutics AG | Production and use of a targeted diagnostic system |
US20030129223A1 (en) * | 2000-10-11 | 2003-07-10 | Targesome, Inc. | Targeted multivalent macromolecules |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6041077B2 (en) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | Cis platinum(2) complex of 1,2-diaminocyclohexane isomer |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
GR75598B (en) | 1980-04-29 | 1984-08-01 | Sanofi Sa | |
US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4565696A (en) | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
US4925661A (en) | 1984-04-19 | 1990-05-15 | Leaf Huang | Target-specific cytotoxic liposomes |
US4789633A (en) | 1984-04-19 | 1988-12-06 | University Of Tennessee Research Corporation | Fused liposome and acid induced method for liposome fusion |
US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US4762915A (en) * | 1985-01-18 | 1988-08-09 | Liposome Technology, Inc. | Protein-liposome conjugates |
US5026651A (en) | 1985-04-25 | 1991-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the production of human transferrin |
PH26160A (en) * | 1985-08-19 | 1992-03-18 | Univ Texas | Pharmaceutical compositions consisting of acylated phospholipids |
US4983397A (en) | 1985-08-19 | 1991-01-08 | Board Of Regents, University Of Texas System | Pharmaceutical compositions consisting of acylated phospholipids |
US5384127A (en) | 1985-10-18 | 1995-01-24 | Board Of Regents, The University Of Texas System | Stable liposomal formulations of lipophilic platinum compounds |
JPH0714865B2 (en) | 1986-10-28 | 1995-02-22 | 武田薬品工業株式会社 | Liposome preparation and method for producing the same |
US5049390A (en) | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
FR2631826B1 (en) | 1988-05-27 | 1992-06-19 | Centre Nat Rech Scient | PARTICULATE VECTOR USEFUL IN PARTICULAR FOR THE TRANSPORT OF BIOLOGICALLY ACTIVATED MOLECULES AND METHOD FOR THE PREPARATION THEREOF |
JPH0720857B2 (en) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
ES2188580T3 (en) | 1989-08-02 | 2003-07-01 | Mitra Medical Technology Ab | SYSTEM FOR USE IN A THERAPEUTIC OR DIAGNOSTIC TREATMENT METHOD. |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
US6509032B1 (en) | 1991-08-28 | 2003-01-21 | Mcmaster University | Cationic amphiphiles |
US5292524A (en) | 1991-09-06 | 1994-03-08 | California Institute Of Technology | Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus |
JPH0776230B2 (en) | 1992-01-13 | 1995-08-16 | 田中貴金属工業株式会社 | Method for producing platinum compound |
JP2673331B2 (en) | 1993-01-12 | 1997-11-05 | 田中貴金属工業 株式会社 | Optically pure cis-oxalate (trans-1-1,2-cyclohexanediamine) platinum (▲ II ▼) |
JPH06287021A (en) | 1992-04-22 | 1994-10-11 | Tanaka Kikinzoku Kogyo Kk | Optical resolution of optically active platinum complex compound |
US20030190638A1 (en) | 1992-05-13 | 2003-10-09 | Board Of Regents, The University Of Texas System | Methods of screening for compounds that derepress or increase telomerase activity |
US20030100489A1 (en) | 1992-10-16 | 2003-05-29 | Beach David H. | Cell-cycle regulatory proteins, and uses related thereto |
US5962316A (en) | 1992-10-16 | 1999-10-05 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
WO1994026254A1 (en) | 1993-05-17 | 1994-11-24 | The Liposome Company, Inc. | Incorporation of taxol into liposomes and gels |
JP3025602B2 (en) | 1993-05-21 | 2000-03-27 | デビオファーム エス.アー. | Method for producing optically high purity cis-oxalate (trans-l-l, 2-cyclohexanediamine) platinum (II) complex |
US5534241A (en) | 1993-07-23 | 1996-07-09 | Torchilin; Vladimir P. | Amphipathic polychelating compounds and methods of use |
ATE222752T1 (en) * | 1993-10-06 | 2002-09-15 | Amgen Inc | STABLE PROTEIN PHOSPHOLIPID COMPOSITIONS AND METHODS |
WO1995016774A1 (en) | 1993-12-17 | 1995-06-22 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
US6057299A (en) | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
JP3590983B2 (en) * | 1994-03-04 | 2004-11-17 | 日本油脂株式会社 | Phospholipid derivatives |
ATE219688T1 (en) | 1994-03-28 | 2002-07-15 | Nycomed Imaging As | LIPOSOMES CONTAINING AN X-RAY OR ULTRASONIC CONTRAST AGENT |
ATE187160T1 (en) | 1994-07-29 | 1999-12-15 | Abbott Lab | METHOD FOR PRODUCING A SUBSTITUTED 2,5-DIAMINO-3-HYDROXY HEXANES |
ATE197249T1 (en) | 1994-08-08 | 2000-11-15 | Debiopharm Sa | STABLE MEDICINAL PRODUCT CONTAINING OXALIPLATIN |
JPH10507450A (en) * | 1994-10-14 | 1998-07-21 | ザ リポソーム カンパニー、インコーポレーテッド | Ether lipid liposomes and their therapeutic use |
DE69531722T2 (en) | 1994-11-11 | 2004-07-01 | Debiopharm S.A. | Carcinostatic compositions containing cis-oxaliplatin and one or more other compatible carcinostats |
US5786214A (en) | 1994-12-15 | 1998-07-28 | Spinal Cord Society | pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system |
US6008202A (en) | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
TW319763B (en) | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
US5780052A (en) | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
US5834012A (en) | 1995-05-03 | 1998-11-10 | Roman Perez-Soler | Lipid complexed topoisomerase I inhibitors |
US20020022264A1 (en) | 1995-05-26 | 2002-02-21 | Sullivan Sean M. | Delivery vehicles comprising stable lipid/nucleic acid complexes |
US6825174B2 (en) | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
JPH09278785A (en) | 1996-04-10 | 1997-10-28 | Tanaka Kikinzoku Kogyo Kk | Production of platinum compound |
FR2740686B1 (en) | 1995-11-03 | 1998-01-16 | Sanofi Sa | STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION |
US6428977B1 (en) | 1995-12-20 | 2002-08-06 | Curis, Inc. | Signalin family of TGFβ signal transduction proteins, and uses related thereto |
JP3735921B2 (en) | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | GPIb / lipid complex and uses thereof |
AU2112697A (en) | 1996-02-09 | 1997-08-28 | Pi-Wan Cheng | Receptor ligand-facilitated delivery of biologically active molecules |
JP3862758B2 (en) | 1996-03-11 | 2006-12-27 | 喜徳 喜谷 | Binuclear platinum complex, preparation method thereof and pharmaceutical composition containing the complex |
WO1997035560A1 (en) | 1996-03-28 | 1997-10-02 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved echogenic liposome compositions |
JP3154399B2 (en) | 1996-07-04 | 2001-04-09 | デビオファーム エス.アー. | Method for producing platinum compound |
US6228391B1 (en) | 1996-05-02 | 2001-05-08 | Terumo Kabushiki Kaisha | Amidine derivatives and drug carriers comprising the same |
ES2208946T3 (en) | 1996-08-23 | 2004-06-16 | Sequus Pharmaceuticals, Inc. | LIPOSOMES CONTAINING A CISPLATIN COMPOUND. |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
IL130822A (en) | 1996-10-15 | 2005-12-18 | Elan Pharm Inc | N-acyl phosphatidylethanolamine-mediated liposomaldrug delivery |
US6087325A (en) * | 1996-10-15 | 2000-07-11 | The Liposome Company, Inc. | Peptide-lipid conjugates |
AU5729898A (en) | 1996-12-18 | 1998-07-15 | Emory University | Polycationic oligomers |
BR9808221A (en) | 1997-03-07 | 2000-05-16 | Sanofi Winthrop Inc | Tumor treatment method. |
DE19709704C2 (en) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Use of a liquid preparation of xenon for intravenous administration when inducing and / or maintaining anesthesia |
JPH10253632A (en) | 1997-03-10 | 1998-09-25 | Nissui Pharm Co Ltd | Method, kit and device for analysis |
US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
US6272370B1 (en) | 1998-08-07 | 2001-08-07 | The Regents Of University Of Minnesota | MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging |
WO1998059035A2 (en) | 1997-06-25 | 1998-12-30 | The Goverment Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health | Serum-free cell growth medium |
US6165719A (en) | 1997-07-15 | 2000-12-26 | The Regents Of The University Of California | hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target |
DE69838584T2 (en) | 1997-08-04 | 2008-06-26 | Cell Genesys, Inc., Foster City | ENHANCERS OF HUMAN GLANDULAR CALLIQUE, VECTORS CONTAINING HIM, AND METHODS FOR ITS USE |
AU742438C (en) | 1997-10-02 | 2003-05-22 | Lantheus Medical Imaging, Inc. | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
US6749863B1 (en) | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
WO1999041403A1 (en) | 1998-02-12 | 1999-08-19 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
GB9804013D0 (en) | 1998-02-25 | 1998-04-22 | Sanofi Sa | Formulations |
US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
CA2346564C (en) | 1998-10-14 | 2011-05-03 | Debiopharm S.A. | Oxaliplatinum preparation packaging |
US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
US6723338B1 (en) | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
AU5136100A (en) | 1999-05-17 | 2000-12-05 | Avi Biopharma, Inc. | Combined approach to treatment of cancer with hcg vaccines |
JP2001002592A (en) | 1999-06-18 | 2001-01-09 | Dai Ichi Seiyaku Co Ltd | Composition for gene-transducing |
US6280054B1 (en) * | 1999-07-02 | 2001-08-28 | Zight Corporation | Image generator having an improved illumination system |
US6242188B1 (en) | 1999-07-30 | 2001-06-05 | Applied Gene Technologies, Inc. | Sample processing to release nucleic acids for direct detection |
EP1204241A1 (en) * | 1999-08-09 | 2002-05-08 | Fujitsu Limited | Package control device and method |
ES2206288T3 (en) | 1999-08-30 | 2004-05-16 | Debiopharm S.A. | STABLE PHARMACEUTICAL PREPARATION OF OXYLIPLATINE FOR PARENTERAL ADMINISTRATION. |
CN1433478A (en) | 1999-12-30 | 2003-07-30 | 诺瓦提斯公司 | Novel colloid synthetic vectors for gene therapy |
CA2394717C (en) | 1999-12-30 | 2011-05-17 | Judith K. Gwathmey | Iron chelator delivery system |
US7034006B2 (en) * | 2000-01-10 | 2006-04-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
US7001735B2 (en) | 2000-03-01 | 2006-02-21 | Albert Einstein College Of Medicine Of Yeshiva University | Glucose transporter/sensor protein and uses thereof |
AU2001236062A1 (en) | 2000-03-02 | 2001-09-12 | Yasuo Ikeda | Gpib-lipid bond construct and use thereof |
JP4449147B2 (en) | 2000-03-22 | 2010-04-14 | 日油株式会社 | Method for producing phosphatidylethanolamine derivative |
FR2806727A1 (en) | 2000-03-23 | 2001-09-28 | Pf Medicament | MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING IN THE N-TERMINAL END A GLUTAMIC ACID OR GLUTAMINE IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION SALT |
EP1272160B1 (en) | 2000-04-12 | 2007-01-17 | Liplasome Pharma A/S | Lipid-based drug delivery systems for topical application |
WO2001082899A2 (en) | 2000-05-03 | 2001-11-08 | Mbt Munich Biotechnology Ag | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
US20030059461A1 (en) | 2000-06-06 | 2003-03-27 | Sibtech, Inc. | Molecular delivery vehicle for delivery of selected compounds to targets |
US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
WO2002020570A2 (en) | 2000-09-11 | 2002-03-14 | Institut Pasteur | Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening |
US20040234588A1 (en) | 2000-09-21 | 2004-11-25 | University Of Georgia Research Foundation, Inc. | Artificial lipoprotein carrier system for bioactive materials |
EP1324758B1 (en) | 2000-10-03 | 2005-01-12 | Debiopharm S.A. | Plga/pla-type polymer microspheres encapsulating a water-soluble substance and process thereof |
JP2004524516A (en) | 2000-12-12 | 2004-08-12 | オーストラリアン インスティチュート オブ マリーン サイエンス | Paralytic shellfish poison assay |
AU2002223013A1 (en) | 2000-12-12 | 2002-06-24 | Debiopharm S.A. | Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same |
US6897196B1 (en) | 2001-02-07 | 2005-05-24 | The Regents Of The University Of California | pH sensitive lipids based on ortho ester linkers, composition and method |
US6703524B2 (en) | 2001-02-20 | 2004-03-09 | Lkt Laboratories, Inc. | Organoselenium compounds for cancer chemoprevention |
ATE365037T1 (en) | 2001-03-02 | 2007-07-15 | Debiopharm Sa | USE OF A BOTTLE CONTAINING OXALIPLATIN SOLUTION |
FI113840B (en) | 2001-03-26 | 2004-06-30 | Ctt Cancer Targeting Tech Oy | Use of matrix metalloproteinase inhibitors in targeting liposomes |
US20040049022A1 (en) | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
US20030203865A1 (en) | 2001-04-30 | 2003-10-30 | Pierrot Harvie | Lipid-comprising drug delivery complexes and methods for their production |
WO2002089772A1 (en) | 2001-05-09 | 2002-11-14 | Inex Pharmaceuticals Corporation | Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents |
US20030108986A1 (en) | 2001-06-21 | 2003-06-12 | Euroscreen, S.A. | Compositions and methods comprising G-protein coupled receptors |
WO2003004505A1 (en) | 2001-07-02 | 2003-01-16 | Debiopharm S.A. | Oxaliplatin active substance with a very low content of oxalic acid |
US20030096299A1 (en) | 2001-07-09 | 2003-05-22 | Valerie Wittamer | Natural ligand of G protein coupled receptor ChemR23 and uses thereof |
CA2457148A1 (en) | 2001-08-20 | 2003-02-27 | Transave, Inc. | Treatment of cancers by inhalation of stable platinum-containing formulations |
DE10144252A1 (en) | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanoparticles with biologically active TNF immobilized on them |
AU2002330139A1 (en) | 2001-10-03 | 2003-04-14 | Vanderbilt University | In vivo panning for ligands to radiation-induced molecules |
WO2003044214A2 (en) | 2001-11-20 | 2003-05-30 | Baylor College Of Medicine | Methods and compositions in checkpoint signaling |
JP4468617B2 (en) | 2001-12-04 | 2010-05-26 | デビオファーム エス.アー. | Method for concomitant administration of anticancer agents and anticancer agents that can be used in combination |
US6476068B1 (en) | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
AU2003202542A1 (en) | 2002-01-07 | 2003-07-24 | Euroscreen S.A. | Ligand for g-protein coupled receptor gpr43 and uses thereof |
US20030220284A1 (en) | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
KR101017732B1 (en) | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | Internalizing anti-CD74 antibodies and methods of use |
CA2513044A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
WO2003082907A1 (en) | 2002-03-29 | 2003-10-09 | Euroscreen Sa | Ligands for g protein coupled receptor gpr7 and uses thereof |
CA2391438A1 (en) | 2002-05-01 | 2003-11-01 | Procyon Biopharma Inc. | Psp94 diagnostic reagents and assays |
US20030228285A1 (en) | 2002-05-03 | 2003-12-11 | Mien-Chie Hung | Bipartite T-cell factor (Tcf)-responsive promoter |
US7460960B2 (en) | 2002-05-10 | 2008-12-02 | Epitome Biosystems, Inc. | Proteome epitope tags and methods of use thereof in protein modification analysis |
FR2840236B1 (en) | 2002-06-03 | 2005-02-04 | Inst Francais Du Petrole | ZEOLITHIC MEMBRANE OF LOW THICKNESS, ITS PREPARATION AND USE IN SEPARATION |
JP3415131B1 (en) * | 2002-06-03 | 2003-06-09 | メビオファーム株式会社 | Liposome preparation |
US20040022842A1 (en) | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
AU2003244766A1 (en) | 2002-06-07 | 2003-12-22 | Immunomedics, Inc. | Neutrophil imaging methods in cyctic fibrosis |
KR101143035B1 (en) | 2002-06-14 | 2012-05-08 | 이뮤노메딕스, 인코오포레이티드 | Monoclonal antibody hPAM4 |
CA2489469C (en) | 2002-06-14 | 2016-03-22 | Immunomedics, Inc. | Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer |
US6790632B2 (en) | 2002-06-17 | 2004-09-14 | Stephen Eliot Zweig | Membrane receptor reagent and assay |
AU2003245160B2 (en) | 2002-06-28 | 2009-09-24 | Arbutus Biopharma Corporation | Method and apparatus for producing liposomes |
EP1546203B1 (en) | 2002-08-01 | 2012-06-20 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
US20040132652A1 (en) | 2002-08-30 | 2004-07-08 | Shire Biochem Inc. | Pharmaceutical compositions |
WO2004045519A2 (en) | 2002-11-14 | 2004-06-03 | Kirk Sperber | Induction of apoptosis by hiv-1 infected monocytic cells |
CN1711074B (en) | 2002-11-15 | 2010-10-06 | 尼普洛株式会社 | Liposomes |
EP1595546A4 (en) | 2003-02-17 | 2010-08-04 | Mebiopharm Co Ltd | Remedy for cancer |
WO2004094613A2 (en) | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
CA2529027C (en) | 2003-06-13 | 2013-09-10 | Immunomedics, Inc. | D-amino acid peptides |
EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
JP2005154282A (en) | 2003-11-20 | 2005-06-16 | Mebiopharm Co Ltd | Method for producing gas-sealed liposome |
US7582430B2 (en) * | 2004-01-20 | 2009-09-01 | United States Of America As Represented By The Secretary Of The Army | Immunoliposome-nucleic acid amplification (ILNAA) assay |
US7212869B2 (en) * | 2004-02-04 | 2007-05-01 | Medtronic, Inc. | Lead retention means |
EP1579850A3 (en) | 2004-03-15 | 2009-12-16 | Nipro Corporation | A pharmaceutical composition containing liposomes for treating a cancer |
JP2006248978A (en) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | New liposome preparation |
WO2008030818A2 (en) | 2006-09-05 | 2008-03-13 | Mebiopharm Co., Ltd. | Novel liposome compositions |
JP5345792B2 (en) | 2008-02-19 | 2013-11-20 | テイ・エス テック株式会社 | Vehicle storage seat |
JP5331648B2 (en) | 2009-10-22 | 2013-10-30 | 株式会社日立製作所 | How to modify a pulverized coal boiler |
-
2005
- 2005-03-10 JP JP2005067469A patent/JP2006248978A/en active Pending
-
2006
- 2006-03-08 SI SI200631892T patent/SI1863448T1/en unknown
- 2006-03-08 ES ES06737793.7T patent/ES2529453T3/en active Active
- 2006-03-08 CN CN2006800159670A patent/CN101170995B/en not_active Expired - Fee Related
- 2006-03-08 US US11/371,586 patent/US7829113B2/en not_active Expired - Fee Related
- 2006-03-08 PL PL06737793T patent/PL1863448T3/en unknown
- 2006-03-08 BR BRPI0608297-1A patent/BRPI0608297A2/en not_active IP Right Cessation
- 2006-03-08 KR KR1020077023219A patent/KR101352490B1/en not_active IP Right Cessation
- 2006-03-08 MX MX2007010996A patent/MX2007010996A/en active IP Right Grant
- 2006-03-08 ZA ZA200708600A patent/ZA200708600B/en unknown
- 2006-03-08 CA CA002600446A patent/CA2600446A1/en not_active Abandoned
- 2006-03-08 HU HUE06737793A patent/HUE024290T2/en unknown
- 2006-03-08 PT PT67377937T patent/PT1863448E/en unknown
- 2006-03-08 DK DK06737793.7T patent/DK1863448T3/en active
- 2006-03-08 WO PCT/US2006/008650 patent/WO2006099169A2/en active Application Filing
- 2006-03-08 RU RU2007137492/15A patent/RU2454229C2/en not_active IP Right Cessation
- 2006-03-08 EP EP06737793.7A patent/EP1863448B1/en active Active
- 2006-03-08 NZ NZ561569A patent/NZ561569A/en not_active IP Right Cessation
- 2006-03-08 AU AU2006223329A patent/AU2006223329B2/en not_active Ceased
- 2006-03-08 JP JP2008500977A patent/JP5438317B2/en not_active Expired - Fee Related
-
2007
- 2007-10-09 NO NO20075136A patent/NO20075136L/en not_active Application Discontinuation
-
2008
- 2008-05-28 HK HK08105936.8A patent/HK1111625A1/en not_active IP Right Cessation
-
2010
- 2010-09-27 US US12/891,568 patent/US8758810B2/en not_active Expired - Fee Related
-
2014
- 2014-05-09 US US14/274,377 patent/US20140363491A1/en not_active Abandoned
-
2015
- 2015-02-06 CY CY20151100123T patent/CY1116075T1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986004232A1 (en) * | 1985-01-18 | 1986-07-31 | Cooper-Lipotech, Inc. | Liposome composition and method |
US5419914A (en) * | 1990-10-09 | 1995-05-30 | Vestar, Inc. | Phospholipid analogue vesicle |
WO1996021658A1 (en) * | 1995-01-09 | 1996-07-18 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
US5891468A (en) * | 1996-10-11 | 1999-04-06 | Sequus Pharmaceuticals, Inc. | Fusogenic liposome compositions and method |
US20030129223A1 (en) * | 2000-10-11 | 2003-07-10 | Targesome, Inc. | Targeted multivalent macromolecules |
EP1209469A1 (en) * | 2000-11-22 | 2002-05-29 | Vectron Therapeutics AG | Production and use of a targeted diagnostic system |
Non-Patent Citations (1)
Title |
---|
MARUYAMA K ET AL: "Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT)", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 98, no. 2, 11 August 2004 (2004-08-11), pages 195 - 207, XP004521710, ISSN: 0168-3659 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7829113B2 (en) | 2005-03-10 | 2010-11-09 | Mebiopharm Co., Ltd. | Liposome compositions |
US8758810B2 (en) | 2005-03-10 | 2014-06-24 | Mebiopharm Co., Ltd. | Liposome compositions |
Also Published As
Publication number | Publication date |
---|---|
ZA200708600B (en) | 2009-01-28 |
US8758810B2 (en) | 2014-06-24 |
EP1863448B1 (en) | 2014-11-26 |
US20140363491A1 (en) | 2014-12-11 |
CY1116075T1 (en) | 2017-02-08 |
KR101352490B1 (en) | 2014-02-04 |
ES2529453T3 (en) | 2015-02-20 |
HUE024290T2 (en) | 2016-01-28 |
CA2600446A1 (en) | 2006-09-21 |
JP2008538105A (en) | 2008-10-09 |
SI1863448T1 (en) | 2015-03-31 |
NZ561569A (en) | 2011-03-31 |
JP5438317B2 (en) | 2014-03-12 |
EP1863448A2 (en) | 2007-12-12 |
BRPI0608297A2 (en) | 2009-12-08 |
CN101170995B (en) | 2013-01-16 |
CN101170995A (en) | 2008-04-30 |
NO20075136L (en) | 2007-12-07 |
AU2006223329B2 (en) | 2011-11-17 |
KR20080002819A (en) | 2008-01-04 |
US7829113B2 (en) | 2010-11-09 |
PL1863448T3 (en) | 2015-05-29 |
DK1863448T3 (en) | 2015-02-16 |
US20060222696A1 (en) | 2006-10-05 |
HK1111625A1 (en) | 2008-08-15 |
RU2454229C2 (en) | 2012-06-27 |
AU2006223329A1 (en) | 2006-09-21 |
WO2006099169A2 (en) | 2006-09-21 |
MX2007010996A (en) | 2007-11-07 |
JP2006248978A (en) | 2006-09-21 |
RU2007137492A (en) | 2009-04-20 |
PT1863448E (en) | 2015-02-10 |
US20110081404A1 (en) | 2011-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006099169A3 (en) | Novel liposome compositions | |
WO2008030818A3 (en) | Novel liposome compositions | |
WO2005120461A3 (en) | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof | |
WO2007092620A3 (en) | Stable formulations, and methods of their preparation and use | |
WO2007038459A3 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
CL2007002513A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED ISOINDOLIN, INTERMEDIATE COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND PREVENTION OF DISEASES SUCH AS CANCER, PAIN, MACULAR DEGENERATION, AMONG OTHERS. | |
WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
CL2007002708A1 (en) | COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRIDINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, CAQUEXY, INFLAMMATORY DISORDERS, AMONG OTHERS. | |
TW200716646A (en) | (S)-N-methylnaltrexone | |
MX2009006704A (en) | New compounds. | |
WO2006052767A3 (en) | Compositions and methods for stabilizing liposomal camptothecin formulations | |
WO2007064857A8 (en) | Amphoteric liposome formulation | |
WO2007093880A3 (en) | Novel pyrone-indole derivatives and process for their preparation | |
WO2005112633A3 (en) | Compounds and compositions for delivering active agents | |
WO2007105015A3 (en) | DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID | |
IL226313A0 (en) | A method for producing gamma-carboxylated human prothrombin isolated prothrombin produced by such method, pharmaceutical composition comprising it and use thereof as medicaments and in the manufacture of medicaments for coagulation therapy | |
WO2006055352A3 (en) | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally | |
WO2008076954A3 (en) | Heterocycle compounds and methods of use thereof | |
WO2010121164A3 (en) | 1,4-benzodiazepinone compounds and their use in treating cancer | |
WO2007025146A3 (en) | Balsalazide formulations and manufacture and use thereof | |
WO2008063808A3 (en) | Encapsulated peptide amphiphile nanostructures | |
WO2007056236A3 (en) | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously | |
CL2008000495A1 (en) | Compounds derived from tetrahydro-pyrazolo [4,3-c] pyridine; pharmaceutical composition; and use in the treatment of diseases such as allergies, inflammation, pain, cancer, among others. | |
WO2009053628A3 (en) | Novel compounds, preparation and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680015967.0 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2600446 Country of ref document: CA Ref document number: 2008500977 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/010996 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3440/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 561569 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006223329 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006737793 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007137492 Country of ref document: RU Ref document number: 1020077023219 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006223329 Country of ref document: AU Date of ref document: 20060308 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0608297 Country of ref document: BR Kind code of ref document: A2 |